LLY

956.19

-1.64%↓

JNJ

221.61

-0.09%↓

ABBV

200.92

-1.19%↓

UNH

373.87

+1.76%↑

AZN

182.54

+0.47%↑

LLY

956.19

-1.64%↓

JNJ

221.61

-0.09%↓

ABBV

200.92

-1.19%↓

UNH

373.87

+1.76%↑

AZN

182.54

+0.47%↑

LLY

956.19

-1.64%↓

JNJ

221.61

-0.09%↓

ABBV

200.92

-1.19%↓

UNH

373.87

+1.76%↑

AZN

182.54

+0.47%↑

LLY

956.19

-1.64%↓

JNJ

221.61

-0.09%↓

ABBV

200.92

-1.19%↓

UNH

373.87

+1.76%↑

AZN

182.54

+0.47%↑

LLY

956.19

-1.64%↓

JNJ

221.61

-0.09%↓

ABBV

200.92

-1.19%↓

UNH

373.87

+1.76%↑

AZN

182.54

+0.47%↑

Home・Lista de Ações・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Abrir

SetorSaúde

31.46 1

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

30.17

Máximo

32.1

Indicadores-chave
By Trading Economics
Rendimento	-28M 22M
Vendas	4.3M 244M
P/E Médio do Setor	11.723 49.8
Margem de lucro	9.224
Funcionários	293
EBITDA	-22M 52M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+38.26% upside

Dividendos
By Dow Jones
Próximos Ganhos	4 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	338M 1.9B
Abertura anterior	30.46
Fecho anterior	31.46

Sentimento de Notícias

By Acuity

58%

42%

293 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Weak Bullish Evidence

29.8 / N/A Suporte e Resistência

Harmony Biosciences Holdings Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

7 de mai. de 2026, 23:58 UTC

Ganhos

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 de mai. de 2026, 22:57 UTC

Ganhos

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 de mai. de 2026, 23:52 UTC

Ganhos

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 de mai. de 2026, 23:45 UTC

Conversa de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 de mai. de 2026, 23:39 UTC

Conversa de Mercado

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 de mai. de 2026, 23:28 UTC

Conversa de Mercado

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 de mai. de 2026, 23:11 UTC

Ganhos

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 de mai. de 2026, 23:06 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 de mai. de 2026, 23:05 UTC

Ganhos

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 de mai. de 2026, 23:04 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 de mai. de 2026, 23:03 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 de mai. de 2026, 23:03 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 de mai. de 2026, 23:02 UTC

Ganhos

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 de mai. de 2026, 23:00 UTC

Conversa de Mercado

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 de mai. de 2026, 22:45 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 de mai. de 2026, 22:45 UTC

Conversa de Mercado

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 de mai. de 2026, 22:42 UTC

Ganhos

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 de mai. de 2026, 22:33 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 de mai. de 2026, 22:32 UTC

Ganhos

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 de mai. de 2026, 22:31 UTC

Ganhos

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 de mai. de 2026, 22:31 UTC

Ganhos

Macquarie: 68% of FY Income From International >MQG.AU

7 de mai. de 2026, 22:30 UTC

Ganhos

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 de mai. de 2026, 22:30 UTC

Ganhos

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 de mai. de 2026, 22:29 UTC

Ganhos

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 de mai. de 2026, 22:28 UTC

Ganhos

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 de mai. de 2026, 22:28 UTC

Ganhos

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 de mai. de 2026, 22:27 UTC

Ganhos

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 de mai. de 2026, 22:27 UTC

Ganhos

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 de mai. de 2026, 22:26 UTC

Ganhos

Macquarie to End Share Buyback Extended in November>MQG.AU

7 de mai. de 2026, 22:25 UTC

Ganhos

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Comparação entre Pares

Variação de preço

Harmony Biosciences Holdings Inc Previsão

Preço-alvo

By TipRanks

38.26% parte superior

Previsão para 12 meses

Média 43.44 USD 38.26%

Máximo 72 USD

Mínimo 28 USD

Com base em 9 analistas de Wall Street que oferecem metas de preço de 12 meses para Harmony Biosciences Holdings Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

9 ratings

Comprar

Manter

Vender

Com base em 9 analistas que deram avaliações de ações para Harmony Biosciences Holdings Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

29.8 / N/ASuporte e Resistência

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimento

By Acuity

293 / 347 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.